“New imaging has rapidly changed the advanced prostate cancer landscape, and all of the existing studies that we have are based on older imaging,” says Dr. Henderson.
R. Jonathan Henderson, MD, is a practicing urologist at Arkansas Urology. In this interview, Dr. Henderson discusses some of the key takeaways from the APCC Optimization panel, which took place during the 2022 LUGPA Annual Meeting in Chicago, Illinois.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.